New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells

被引：7

作者：

Santucci, Maria Alessandra ^{[1
]}

Mancini, Manuela ^{[1
]}

Corradi, Valentina ^{[2
]}

lacobucci, Ilaria ^{[1
]}

Martinelli, Giovanni ^{[1
]}

Botta, Maurizio ^{[2
]}

Schenone, Silvia ^{[3
]}

机构：

[1] Univ Bologna Policlin S Orsola, Ist Ematol Lorenzo & Ariosto Seragnoli, I-40138 Bologna, Italy

[2] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy

[3] Univ Genoa, Dipartimento Sci Farmaceut, Genoa, Italy

来源：

INVESTIGATIONAL NEW DRUGS | 2010年 / 28卷 / 06期

关键词：

Chronic myeloid leukemia; Imatinib resistance; Dual SRC/Abl kinase inhibitors; IMATINIB;

D O I：

10.1007/s10637-009-9294-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：876 / 878

页数：3

共 7 条

[1] P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors [J].

Brusa, G ;

Zuffa, E ;

Mancini, M ;

Benvenuti, M ;

Calonghi, N ;

Barbieri, E ;

Santucci, MA .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (03) :359-369

[2] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].

Druker, BJ ;

Tamura, S ;

Buchdunger, E ;

Ohno, S ;

Segal, GM ;

Fanning, S ;

Zimmermann, J ;

Lydon, NB .

NATURE MEDICINE, 1996, 2 (05) :561-566

[3] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[4] Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines [J].

Manetti, Fabrizio ;

Brullo, Chiara ;

Magnani, Matteo ;

Mosci, Francesca ;

Chelli, Beatrice ;

Crespan, Emmanuele ;

Schenone, Silvia ;

Naldini, Antonella ;

Bruno, Olga ;

Trincavelli, Maria Letizia ;

Maga, Giovanni ;

Carraro, Fabio ;

Martini, Claudia ;

Bondavalli, Francesco ;

Bottat, Maurizio .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (05) :1252-1259

[5] Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia [J].

Quintas-Cardama, Alfonso ;

Cortes, Jorge .

CLINICAL CANCER RESEARCH, 2008, 14 (14) :4392-4399

[6] C6-Unsubstituted Pyrazolo[3,4-d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines [J].

Santucci, Maria Alessandra ;

Corradi, Valentina ;

Mancini, Manuela ;

Manetti, Fabrizio ;

Radi, Marco ;

Schenone, Silvia ;

Botta, Maurizio .

CHEMMEDCHEM, 2009, 4 (01) :118-126

[7] Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia [J].

Soverini, Simona ;

Colarossi, Sabrina ;

Gnani, Alessandra ;

Rosti, Gianantonio ;

Castagnetti, Fausto ;

Poerio, Angela ;

Iacobucci, Ilaria ;

Amabile, Marilina ;

Abruzzese, Elisabetta ;

Orlandi, Ester ;

Radaelli, Franca ;

Ciccone, Fabrizio ;

Tiribelli, Mario ;

di Lorenzo, Roberto ;

Caracciolo, Clementina ;

Izzo, Barbara ;

Pane, Fabrizio ;

Saglio, Giuseppe ;

Baccarani, Michele ;

Martinelli, Giovanni .

CLINICAL CANCER RESEARCH, 2006, 12 (24) :7374-7379

← 1 →